Nemluvio Dosage

Vaccination Prior to Treatment

2.2 Recommended Dosage

Adult Patients Weighing Less Than 90 kg: The recommended subcutaneous dosage of NEMLUVIO for adult patients weighing less than 90 kg is an initial dose of 60 mg (two 30 mg injections), followed by 30 mg given every 4 weeks (Q4W).

Adult Patients Weighing 90 kg or More: The recommended subcutaneous dosage of NEMLUVIO for adult patients weighing 90 kg or more is an initial dose of 60 mg (two 30 mg injections), followed by 60 mg given every 4 weeks (Q4W).

Missed Dose

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.

Important Administration Instructions

• NEMLUVIO is administered by subcutaneous injection.
• NEMLUVIO is intended for use under the guidance of a healthcare provider. Prior to the first injection, provide patients and/or caregivers with proper training on the preparation and administration of NEMLUVIO. Patients may self-inject NEMLUVIO after receiving training on subcutaneous injection techniques.
• For the initial dose, administer each of the two NEMLUVIO injections at different injection sites.
• Administer subcutaneous injection into the front upper thighs or abdomen except for the 2 inches (5 cm) around the navel. Injection in upper arm should only be performed by a caregiver or healthcare professional.
• Alternate the injection site with each injection. Do not inject NEMLUVIO into skin that is tender, inflamed, swollen, damaged or has bruises or scars or open wounds.
• Refer to the Instructions for Use for complete administration instructions with illustrations.

Preparation for Use of NEMLUVIO

• Before injection, remove NEMLUVIO carton from the refrigerator and allow to reach room temperature (30-45 minutes).
• Inspect NEMLUVIO visually prior to reconstitution. NEMLUVIO is supplied in a single-dose pre-filled dual-chamber pen with white powder in one chamber and a clear diluent in the other chamber. Do not use if powder is not white, or if diluent is cloudy or contains visible particles.
• NEMLUVIO must be reconstituted prior to administration.
• Following reconstitution, each pre-filled pen delivers 30 mg/0.49 mL as a clear and colorless to slightly yellow solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if the reconstituted solution has discoloration or contains particles.
• Use NEMLUVIO pens within 4 hours after reconstitution. Discard unused reconstituted NEMOLUVIO pens after 4 hours.
• Discard any unused portions after administration
• Refer to the Instructions for Use for complete preparation instructions with illustrations [see Instructions for Use.]